Gland Pharma has reported a robust start to fiscal year 2027, with Q1 FY27 revenues reaching INR18,003 million, a 20% increase year-on-year. Profit after tax saw a significant jump of 47% to INR3,170 million. The company attributed its performance to strong momentum in its CDMO and B2B businesses, successful product launches, and improved operational efficiencies.
Gland Pharma Reports Strong Q1 FY27 Performance
Gland Pharma Limited announced its financial results for the first quarter of fiscal year 2027 (ended June 30, 2026), showcasing healthy growth across key financial metrics. The company reported consolidated revenues of INR18,003 million, marking a substantial 20% year-on-year increase. This growth was driven by continued strength in its CDMO and B2B businesses, contributions from recent product launches, increasing volumes from existing products, and improved capacity utilization.
Profitability and Margins Surge
Profitability also witnessed a significant uplift, with profit after tax (PAT) growing by 47% year-on-year to INR3,170 million, resulting in a PAT margin of 18%. Adjusted EBITDA stood at INR5,102 million, with margins of 28%, an improvement from 25% in the corresponding quarter of the previous year. The company highlighted that this performance reflects the resilience of its business model and successful execution of strategic priorities.
Segmental and Geographic Performance
The CDMO business continued its strong growth trajectory, contributing 50% of total revenues with INR 8,915 million, a 20% year-on-year increase. The B2B business also performed well, contributing 50% of total revenues with INR 9,088 million, a 19% year-on-year growth. Geographically, the United States remained the largest market, with revenues of INR9,810 million, reflecting a robust 32% year-on-year growth, driven by new product launches and volume expansion. Europe and other regulatory markets saw revenues of INR4,488 million, a 11% year-on-year increase.
Strategic Initiatives and Outlook
Gland Pharma also highlighted strategic developments, including a significant manufacturing and supply agreement for a portfolio of sterilized injectables, expected to generate revenue from calendar year 2029. The company is also investing in capacity expansion through multiple brownfield and greenfield initiatives to support future growth. The company expressed confidence in its CDMO strategy and long-term growth trajectory.
Source: BSE
